Jiangsu Yahong Meditech (SHA:688176) or Asieris Pharmaceuticals signed an investigational drug supply agreement with the US Centers for Disease Control and Prevention for its APL-1202 medication for free-living amoeba infections, according to a Monday press release.
The drug is indicated for free-living amoebae causing amoebic meningoencephalitis, which has a 90% mortality rate, the company said.
The US CDC has also submitted an expanded-access investigational new drug application to the US Food and Drug Administration for the use of APL-1202 in laboratory-confirmed or suspected non-keratitis infections caused by free-living amoeba, Asieris said.
Shares fell 2% during Wednesday's late morning trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。